Flatiron Health announces expansion into oncology real-world evidence generation

Flatiron Health, a leading provider of real-world data (RWD) and analytics solutions for oncology, is expanding its capabilities to generate real-world evidence (RWE). Flatiron’s expansion into RWE generation will allow it to provide its customers with a more comprehensive set of data and analytics solutions to help them improve the lives of cancer patients.

Hot on the heels of their recent news, Flatiron Health has announced the launch of its new Integrated RWE Solutions approach, allowing partners with analytic, scientific, and consultative services to generate robust RWE and insights. Building on their expertise of generating high-quality oncology RWD through extraction and analysis of electronic health record (EHR) information, Flatiron will become a ‘one-stop-shop’ for oncology RWD/E generation across the product lifecycle.

Speaking exclusively to The Evidence Base, Stephanie Reisinger, SVP & General Manager, Real-World Evidence, Flatiron said “Flatiron’s focus for the past decade has been on curating and unlocking real-world oncology data. However, this week’s announcement marks a new chapter that allows us to go beyond real-world data and by leveraging our internal expertise to offer both the data and the analysis necessary to meet burgeoning oncology needs.”

Flatiron has established itself as the oncology RWD partner of choice for many pharmaceutical companies. Their Integrated RWE Solutions approach allows stakeholders, including practicing oncology physicians and clinicians, to actively manage their data curation and provides a more flexible way to get the oncology evidence they need. By tailoring solutions to fit each customer’s unique needs, Flatiron can deliver high-quality, actionable insights that drive better outcomes for patients. Flatiron’s RWD integration is seamlessly embedded within OncoEMR®, ensuring complete data is traceable and auditable from its original source documents. Customers can therefore leverage Flatiron’s deep expertise in the technical aspects involved in interpreting and analyzing oncology EHR data using a combination of machine learning and human approaches to ensure the RWE generated is accurate and reliable.

Reisinger continued, “Through our learnings over the last ten years, we have developed extensive data empathy, also known as a deep and detailed knowledge and understanding of EHR data. Because we own the data from start to finish, we can compress the timeframe by which real/world data studies are run, improving the speed and quality of oncology care available and becoming a more strategic partner to our customers.”

Commenting on the news, a HEOR Director at a large global life sciences company explained, “Flatiron has been a valuable partner, bringing their expertise and newly expanded strategic offerings in real-world data analytics to the table. Their seamless collaborative approach and subject matter knowledge advanced a real-world comparative effectiveness study evaluating treatment-specific sub-cohorts within a broader, real-world biomarker-identified population. Flatiron’s scientific innovation and breadth of analytic capabilities have greatly contributed to generating impactful evidence for this oncology research project.”